Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Study Questions:

What are the efficacy and safety of aliskiren, a direct renin inhibitor, among patients with type 2 diabetes mellitus already taking an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-receptor blocker (ARB)?